{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:32:50Z","timestamp":1780709570245,"version":"3.54.1"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec id=\"ab-eoi240037-4\"><jats:title>Importance<\/jats:title><jats:p>The involvement of chronic inflammation in the pathogenesis of age-related macular degeneration (AMD) opens therapeutic possibilities to AMD management.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240037-5\"><jats:title>Objective<\/jats:title><jats:p>To determine whether Janus kinase inhibitors (JAKis) are associated with a reduced risk of AMD development in patients with autoimmune diseases.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240037-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective observational cohort study used administrative claims data from Merative MarketScan research databases (Commercial and Medicare Supplemental) and Optum Clinformatics Data Mart databases between January 1, 2010, and January 31, 2022. Patients with autoimmune diseases satisfying study eligibility criteria and who received JAKi treatment (9126 in MarketScan and 5667 in Optum) were propensity score matched (1:1) to identical numbers of study-eligible patients who received non\u2013JAKi-based immunotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240037-7\"><jats:title>Exposure<\/jats:title><jats:p>Treatment duration of 6 months or longer.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240037-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Incidence rates of AMD (exudative and nonexudative) over the first 6 to 18 months of treatment were determined, and bayesian Poisson regression models were used to estimate incidence rate ratios, 95% CIs, and posterior probabilities of AMD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240037-9\"><jats:title>Results<\/jats:title><jats:p>After matching, female sex represented the majority of the patient population in both MarketScan and Optum (14\u202f019\/18\u202f252 [76.6%] and 8563\/3364 [75.2%], respectively in the JAKi patient population). More than 60% of the patient population was older than 55 years of age in both cohorts. Over the specified treatment period, a 49% relative reduction in incidence of AMD was observed among patients who received JAKi therapy (10\/9126 events; adjusted incidence rate ratio [AIRR], 0.51; 95% CI, 0.19-0.90) vs those who received non-JAKi therapy (43\/9126 events; AIRR, 1 [reference]) in MarketScan, and a 73% relative reduction in incidence of AMD was observed among patients who received JAKi therapy (3\/5667 events; AIRR, 0.27; 95% CI, 0.03-0.74) vs those who received non-JAKi therapy (21\/5667 events; AIRR, 1 [reference]) in Optum. The absolute percentage reductions were 0.36% (MarketScan) and 0.32% (Optum), favoring patients who received JAKi therapy. Posterior probabilities of the adjusted risk being less than unity were 97.6% (MarketScan) and 98.9% (Optum) for those who received JAKi therapy vs those who received non-JAKi therapy in MarketScan and Optum, respectively.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240037-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>JAKi use may be associated with a reduced risk of incident AMD in US adults with major autoimmune diseases. The absolute percentage reduction is consistent with a potential role for JAKi in this population. Future studies with long-term follow-up are recommended to investigate the association between JAKi use and incident AMD in other disease indications. Investigation into the role of systemic inflammation and JAK\u2013signal transducers and activators of transcription signaling in AMD may improve understanding of the pathophysiology of AMD and lead to new treatment options.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.2376","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T15:41:47Z","timestamp":1720712507000},"page":"750","source":"Crossref","is-referenced-by-count":9,"title":["Janus Kinase Inhibitor Therapy and Risk of Age-Related Macular Degeneration in Autoimmune Disease"],"prefix":"10.1001","volume":"142","author":[{"given":"Joelle A.","family":"Hallak","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Genomics Research Center, AbbVie, North Chicago, Illinois"},{"name":"Currently with University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Bay Area Retina Associates, Walnut Creek, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasha","family":"Modi","sequence":"additional","affiliation":[{"name":"New York University Langone Health, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Jing","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mercer","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, New Jersey"},{"name":"Currently with Genesis Research Group, Hoboken, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Sahu","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alobaidi","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Ophthalmology Discovery Research, AbbVie, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Luhrs","sequence":"additional","affiliation":[{"name":"Ophthalmology Discovery Research, AbbVie, Irvine, California"},{"name":"Currently with Bausch + Lomb, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F.","family":"Waring","sequence":"additional","affiliation":[{"name":"Genomics Research Center, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke I.","family":"den Hollander","sequence":"additional","affiliation":[{"name":"Genomics Research Center, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Smaoui","sequence":"additional","affiliation":[{"name":"Genomics Research Center, AbbVie, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"eoi240037r1","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"6","key":"eoi240037r2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000517520","article-title":"Age-related macular degeneration: pathophysiology, management, and future perspectives.","volume":"244","author":"Flores","year":"2021","journal-title":"Ophthalmologica"},{"issue":"12","key":"eoi240037r3","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019.","volume":"140","author":"Rein","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"eoi240037r4","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"2","key":"eoi240037r5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/eye.2010.196","article-title":"The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment.","volume":"25","author":"Wang","year":"2011","journal-title":"Eye (Lond)"},{"issue":"5","key":"eoi240037r6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1189\/jlb.3RI0615-239R","article-title":"Parainflammation, chronic inflammation, and age-related macular degeneration.","volume":"98","author":"Chen","year":"2015","journal-title":"J Leukoc Biol"},{"issue":"2","key":"eoi240037r7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/APO.0000000000000570","article-title":"The role of inflammation in age-related macular degeneration: updates and possible therapeutic approaches.","volume":"12","author":"Arrigo","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"3","key":"eoi240037r8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0002-9394(02)01624-0","article-title":"A role for local inflammation in the formation of drusen in the aging eye.","volume":"134","author":"Anderson","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"13","key":"eoi240037r9","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/cells12131708","article-title":"Beyond the complement cascade: insights into systemic immunosenescence and inflammaging in age-related macular degeneration and current barriers to treatment.","volume":"12","author":"Khan","year":"2023","journal-title":"Cells"},{"issue":"2","key":"eoi240037r10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"eoi240037r11","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41598-020-58510-9","article-title":"A transcriptome-wide association study based on 27 tissues identifies 106 genes potentially relevant for disease pathology in age-related macular degeneration.","volume":"10","author":"Strunz","year":"2020","journal-title":"Sci Rep"},{"issue":"5-a Suppl","key":"eoi240037r12","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.18553\/jmcp.2023.29.5-a.s2","article-title":"Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system.","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"eoi240037r13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaophthalmol.2017.2011","article-title":"Age-related macular degeneration in patients with chronic myeloproliferative neoplasms.","volume":"135","author":"Bak","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"Suppl 271","key":"eoi240037r14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/aos.v100.s271","article-title":"Age-related macular degeneration and myeloproliferative neoplasms\u2014a common pathway.","volume":"100","author":"Liisborg","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"eoi240037r15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ajpath.2023.04.006","article-title":"The emerging role of gut microbiota in age-related macular degeneration.","volume":"193","author":"Xiao","year":"2023","journal-title":"Am J Pathol"},{"issue":"6","key":"eoi240037r16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/aos.v101.6","article-title":"Association between oral metformin use and the risk of age-related macular degeneration: a systematic review with meta-analysis.","volume":"101","author":"Holtz","year":"2023","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"eoi240037r17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","article-title":"Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression. and symptoms.","volume":"14","author":"Mendez Luque","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"eoi240037r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101248","article-title":"Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation.","volume":"43","author":"Liisborg","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"eoi240037r19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/jamaophthalmol.2023.5478","article-title":"Metformin use and age-related macular degeneration in patients without diabetes.","volume":"142","author":"Aggarwal","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi240037r20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic.","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"eoi240037r21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.bbrc.2010.10.042","article-title":"Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK\/STAT pathway.","volume":"402","author":"Kutty","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"eoi240037r22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/jcp.v227.1","article-title":"Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration.","volume":"227","author":"Nagineni","year":"2012","journal-title":"J Cell Physiol"},{"key":"eoi240037r23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/978-1-4419-1399-9","article-title":"The differential role of Jak\/STAT signaling in retinal degeneration.","volume":"664","author":"Lange","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"13","key":"eoi240037r24","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1096\/fsb2.v20.13","article-title":"Differential role of Jak-STAT signaling in retinal degenerations.","volume":"20","author":"Samardzija","year":"2006","journal-title":"FASEB J"},{"key":"eoi240037r25","first-page":"1631","article-title":"Endogenous leukemia inhibitory factor protects photoreceptor cells against light-induced degeneration.","volume":"15","author":"B\u00fcrgi","year":"2009","journal-title":"Mol Vis"},{"issue":"4","key":"eoi240037r26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000085730","article-title":"Activated STAT 3 in choroidal neovascular membranes of patients with age-related macular degeneration.","volume":"219","author":"Fasler-Kan","year":"2005","journal-title":"Ophthalmologica"},{"issue":"19","key":"eoi240037r27","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"6","key":"eoi240037r28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1524-4733.2006.00130.x","article-title":"Too much ado about propensity score models? comparing methods of propensity score matching.","volume":"9","author":"Baser","year":"2006","journal-title":"Value Health"},{"issue":"9","key":"eoi240037r29","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00018-016-2147-8","article-title":"Inflammation and its role in age-related macular degeneration.","volume":"73","author":"Kauppinen","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"eoi240037r30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.survophthal.2017.05.003","article-title":"Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration.","volume":"63","author":"Kersten","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"eoi240037r31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.preteyeres.2017.06.002","article-title":"On phagocytes and macular degeneration.","volume":"61","author":"Guillonneau","year":"2017","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"eoi240037r32","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/emmm.201302692","article-title":"CCR2(+) monocytes infiltrate atrophic lesions in age-related macular disease and mediate photoreceptor degeneration in experimental subretinal inflammation in Cx3cr1 deficient mice.","volume":"5","author":"Sennlaub","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"4","key":"eoi240037r33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1566524016666160324130031","article-title":"STAT3 activation in circulating monocytes contributes to neovascular age-related macular degeneration.","volume":"16","author":"Chen","year":"2016","journal-title":"Curr Mol Med"},{"issue":"3","key":"eoi240037r34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.survophthal.2010.08.007","article-title":"A review and meta-analysis of the association between C-reactive protein and age-related macular degeneration.","volume":"56","author":"Hong","year":"2011","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"eoi240037r35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jamaophthalmol.2013.2303","article-title":"C-reactive protein and the incidence of macular degeneration: pooled analysis of 5 cohorts.","volume":"131","author":"Mitta","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"eoi240037r36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00417-014-2738-8","article-title":"Serum cytokines as biomarkers for age-related macular degeneration.","volume":"253","author":"Nassar","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"373","key":"eoi240037r37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/01621459.1981.10477597","article-title":"Sample size for logistic regression with small response probability.","volume":"76","author":"Whittemore","year":"1981","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"eoi240037r38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/sim.4780080704","article-title":"Sample size tables for logistic regression.","volume":"8","author":"Hsieh","year":"1989","journal-title":"Stat Med"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2820696\/jamaophthalmology_hallak_2024_oi_240037_1723584454.53529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:02:07Z","timestamp":1723734127000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2820696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2376","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}